Phase 1 trial of zolbetuximab in Japanese patients with CLDN18 .2+ gastric or gastroesophageal junction adenocarcinoma
Author:
Affiliation:
1. Department of Gastrointestinal Oncology National Cancer Center Hospital East Chiba Japan
2. Tokyo Medical and Dental University Tokyo Japan
3. Astellas Pharma Inc. Tokyo Japan
4. Astellas Pharma Global Development, Inc. Northbrook IL USA
Funder
Astellas Pharma US
Publisher
Wiley
Subject
Cancer Research,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15684
Reference24 articles.
1. Japanese gastric cancer treatment guidelines 2018 (5th edition)
2. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
3. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
4. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
5. Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials;ESMO Open;2024-08
2. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma;Gastric Cancer;2024-07-02
3. A novel highly sensitive inner filter effect-based fluorescence immunoassay with quantum dots for bioanalysis of zolbetuximab, a monoclonal antibody used for immunotherapy of gastric and gastroesophageal junction adenocarcinoma;Heliyon;2024-07
4. Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer;Digestive Diseases and Sciences;2024-05-20
5. Claudin 18.2 as a novel therapeutic target;Nature Reviews Clinical Oncology;2024-03-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3